Core Hypothesis

Strategic morning light exposure improves cardiometabolic health by activating the SIRT1‑autophagy pathway downstream of the suprachiasmatic nucleus, an effect that does not require extending total sleep duration. Conversely, evening blue‑light filtering only shifts melatonin onset when it also reduces overall photic intensity reaching ipRGCs, because melanopsin signaling saturates at relatively low photon fluxes.

Mechanistic Reasoning

Morning photons (~460‑480 nm) activate melanopsin‑containing retinal ganglion cells, which signal the SCN to increase sympathetic tone and elevate hepatic NAD⁺ levels. This NAD⁺ boost directly activates SIRT1, which deacetylates core autophagy genes (e.g., ATG5, LC3) and enhances autophagic flux in peripheral tissues. Autophagy clears damaged mitochondria and protein aggregates, improving insulin sensitivity and lowering blood pressure. Because this cascade is driven by light‑induced SCN output, it can occur even if sleep duration remains unchanged, provided the light signal occurs within the circadian advance zone (≈0‑4 h after core body temperature minimum).

Evening blue‑light blockade (e.g., amber lenses) reduces photon flux in the 460‑480 nm band but often leaves overall illuminance above the threshold (~10 lux) needed to suppress melatonin via ipRGCs. Melatonin suppression follows a sigmoidal dose‑response; modest reductions in blue photons may not move the stimulus down the curve enough to alter pineal output. Only when total illuminance drops below the saturation point does melatonin onset shift earlier. Hence, the mechanism predicts that blue‑light filters must be combined with dimming ambient light to be effective.

Testable Predictions

1. In a randomized crossover trial, participants receiving 30 min of bright (≥1000 lux) morning light for 3 days will show increased hepatic SIRT1 activity (measured via peripheral blood mononuclear cell SIRT1 deacetylase activity) and higher LC3‑II/I ratios, independent of total sleep time measured by actigraphy.
2. The same morning light protocol will improve fasting glucose and systolic blood pressure relative to a dim‑light control, with mediation analysis indicating that SIRT1‑autophagy changes account for ≥40 % of the cardiometabolic benefit.
3. Evening blue‑light blocking glasses worn at typical indoor illuminance (~200 lux) will not significantly advance melatonin onset (salivary melatonin assay) compared to a clear‑lens control, whereas adding a neutral density filter to reduce overall illuminance to <30 lux will produce a ~30‑minute advance.
4. Combining morning light exposure with evening intensity reduction will yield additive advances in sleep midpoint (>20 min) and greater improvement in cardiometabolic markers than either manipulation alone.

Falsifiability

If morning light fails to increase SIRT1 activity or autophagy markers despite advancing circadian phase, or if evening blue‑light filtration at standard indoor illuminance reliably advances melatonin onset, the hypothesis would be refuted. Similarly, if cardiometabolic improvements occur without detectable changes in SIRT1‑autophagy signaling, the proposed mechanistic link would be unsupported.